Your browser is no longer supported. Please, upgrade your browser.
EPZM Epizyme, Inc. daily Stock Chart
Epizyme, Inc.
Index- P/E- EPS (ttm)-1.91 Insider Own0.40% Shs Outstand103.38M Perf Week-21.82%
Market Cap1.44B Forward P/E- EPS next Y-2.07 Insider Trans-5.47% Shs Float74.68M Perf Month-38.79%
Income-173.20M PEG- EPS next Q-0.74 Inst Own- Short Float9.49% Perf Quarter-43.33%
Sales23.80M P/S60.38 EPS this Y-12.00% Inst Trans2.50% Short Ratio6.29 Perf Half Y28.94%
Book/sh3.09 P/B4.50 EPS next Y25.30% ROA-44.90% Target Price29.22 Perf Year7.50%
Cash/sh3.69 P/C3.77 EPS next 5Y38.00% ROE-59.30% 52W Range9.73 - 27.82 Perf YTD-43.50%
Dividend- P/FCF- EPS past 5Y-3.00% ROI-53.70% 52W High-50.04% Beta2.34
Dividend %- Quick Ratio11.60 Sales past 5Y-10.50% Gross Margin- 52W Low42.78% ATR1.91
Employees203 Current Ratio11.60 Sales Q/Q-55.70% Oper. Margin- RSI (14)38.52 Volatility9.34% 12.33%
OptionableYes Debt/Eq0.00 EPS Q/Q-104.20% Profit Margin- Rel Volume0.61 Prev Close14.26
ShortableYes LT Debt/Eq0.12 EarningsFeb 24 BMO Payout- Avg Volume1.13M Price13.90
Recom1.90 SMA20-17.04% SMA50-31.17% SMA200-13.78% Volume681,723 Change-2.52%
Apr-01-20Downgrade Oppenheimer Outperform → Perform
Mar-04-20Initiated Barclays Overweight $33
Feb-25-20Reiterated H.C. Wainwright Buy $25 → $36
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Dec-06-19Upgrade Morgan Stanley Equal-Weight → Overweight
May-30-19Resumed Citigroup Buy
Jan-07-19Upgrade Leerink Partners Mkt Perform → Outperform
Sep-07-18Resumed Morgan Stanley Equal-Weight
Jul-03-18Downgrade Leerink Partners Outperform → Mkt Perform
Jan-24-18Resumed Jefferies Buy $25
Jan-10-18Initiated Morgan Stanley Overweight $20
Nov-02-17Downgrade RBC Capital Mkts Outperform → Sector Perform $20 → $16
Sep-20-17Initiated Jefferies Buy $23
May-10-17Resumed RBC Capital Mkts Outperform $19 → $20
Apr-13-17Initiated Oppenheimer Outperform
May-10-16Reiterated Mizuho Buy $20 → $18
Apr-05-16Initiated Citigroup Buy $17
Mar-14-16Upgrade H.C. Wainwright Neutral → Buy $25
Mar-10-16Reiterated Wedbush Outperform $33 → $22
Mar-10-16Reiterated Mizuho Buy $26 → $20
Mar-25-20 11:30AM  Epizyme (EPZM) Down 24.9% Since Last Earnings Report: Can It Rebound? Zacks -6.01%
Mar-20-20 06:30AM  Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer Business Wire -6.55%
Mar-06-20 03:41AM  Edited Transcript of EPZM earnings conference call or presentation 24-Feb-20 1:30pm GMT Thomson Reuters StreetEvents
Feb-26-20 06:39AM  Epizyme, Inc. Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next Year Simply Wall St.
Feb-25-20 12:09PM  Analysts: 3 Healthcare Stocks to Buy on Coronavirus Weakness TipRanks
09:38AM  Epizyme (EPZM) Q4 Earnings Miss Estimates, Revenues Beat Zacks
09:28AM  Are Options Traders Betting on a Big Move in Epizyme (EPZM) Stock? Zacks
05:17AM  Here are the Mass.-based firms hit hardest in Monday's stock rout American City Business Journals
Feb-24-20 07:45AM  Epizyme (EPZM) Reports Q4 Loss, Tops Revenue Estimates Zacks -13.02%
06:30AM  Epizyme, Inc. to Host Earnings Call ACCESSWIRE
06:30AM  Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
Feb-23-20 06:38PM  The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace Benzinga
Feb-20-20 08:42AM  Epizyme (EPZM) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-19-20 09:21AM  Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates Zacks
Feb-18-20 06:30AM  Epizyme Announces Date of Fourth Quarter and Full Year 2019 Results and Presentations at Upcoming Investor Conferences Business Wire
Feb-14-20 08:23AM  The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering Benzinga +9.13%
06:30AM  Epizyme Announces FDA Acceptance of New Drug Application for Filing with Priority Review for TAZVERIK (tazemetostat) for the Treatment of Follicular Lymphoma Business Wire
Feb-12-20 06:55AM  Investors Who Bought Epizyme (NASDAQ:EPZM) Shares Three Years Ago Are Now Up 81% Simply Wall St.
Feb-06-20 05:50PM  Epizyme (EPZM) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-05-20 11:52AM  Steven Cohen Renews His Interest in Verastem
Jan-31-20 05:50PM  Epizyme (EPZM) Dips More Than Broader Markets: What You Should Know Zacks
Jan-29-20 09:59AM  Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data Zacks
Jan-24-20 12:00PM  Are You Looking for a Top Momentum Pick? Why Epizyme (EPZM) is a Great Choice Zacks -16.17%
10:44AM  The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study Benzinga
09:57AM  Epizyme Gets FDA Nod for Lead Drug in Epithelioid Sarcoma Zacks
05:52AM  Epizyme's Tazemetostat Drug For Epithelioid Sarcoma Gets Accelerated FDA Approval Benzinga
Jan-23-20 06:07PM  FDA approves local biotech's first rare-cancer drug American City Business Journals
05:16PM  Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma Business Wire
09:34AM  Axsome (AXSM) Completes Patient Randomization in TRD Study Zacks
09:04AM  Benzinga Pro's Top 5 Stocks To Watch For Thurs., Jan. 23, 2020: CODX, LUV, INTC, PAYC, EPZM Benzinga
Jan-22-20 11:30AM  Is Epizyme (EPZM) Outperforming Other Medical Stocks This Year? Zacks
10:00AM  Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance Zacks
08:57AM  Is the Options Market Predicting a Spike in Epizyme (EPZM) Stock? Zacks
Jan-21-20 09:26AM  Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth Zacks
Jan-20-20 02:04PM  The Week Ahead In Biotech: Focus On Epizyme, Merck Ahead Of PDUFA Dates, J&J To Kickstart Big Pharma Earnings Benzinga
09:32AM  Seattle Genetics Up More Than 40% in the Past Year: Here's Why Zacks
Jan-17-20 08:45AM  ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why Zacks
Jan-09-20 04:47PM  Applied Therapeutics Up on Positive Galactosemia Study Data Zacks
Jan-08-20 12:00PM  What Makes Epizyme (EPZM) a Strong Momentum Stock: Buy Now? Zacks
Jan-07-20 10:26AM  Blueprint Medicines Initiates Dosing in Liver Cancer Study Zacks
09:19AM  aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma Zacks
Jan-06-20 06:30AM  Epizyme Announces Exercise of $50 Million Option with Royalty Pharma and Highlights Key 2020 Initiatives to Build Long-Term Value Business Wire
Dec-30-19 09:24AM  3 Healthcare Stocks With Huge FDA Decisions in January TipRanks
Dec-26-19 10:38AM  Epizyme (EPZM) Shares Soar on Lead Candidate's Progress Zacks
Dec-24-19 08:15AM  Will Epizyme Continue to Surge Higher? Zacks
Dec-23-19 10:18AM  Did Hedge Funds Drop The Ball On Epizyme Inc (EPZM) ? Insider Monkey
Dec-19-19 10:02AM  Epizyme Stock Up on Positive Advisory Votes for Tazemetostat Zacks
07:52AM  The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic Benzinga
Dec-18-19 05:27PM  Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Follicular Lymphoma Business Wire +10.47%
02:54PM  Epizyme's stock jumps on 11-0 vote from FDA adcomm MarketWatch
02:00PM  Epizyme Announces FDA Advisory Committee Votes Unanimously in Favor of Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma Business Wire
12:50PM  FDA committee sets stage for Epizyme's first product approval American City Business Journals
11:10AM  FDA Votes Unanimously In Favor Of Epizyme's Tazemetostat Benzinga
08:46AM  Benzinga Pro's Top 5 Stocks To Watch For Wed., Dec. 18, 2019: UPS, MU, EPZM, SLDB, XXII Benzinga
07:05AM  Epizyme (EPZM) Trading of Stock Halted; Oncology Drug Advisory Committee to Review Tazemetostat at 8:00 a.m. ET Today Business Wire
Dec-17-19 09:11AM  5 Biotech Stocks That Have More Than Doubled This Year Zacks
07:25AM  Moving Average Crossover Alert: Epizyme Zacks
Dec-16-19 12:00PM  Epizyme (EPZM) Is Up 10.29% in One Week: What You Should Know Zacks
Dec-15-19 03:49PM  The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week Benzinga
Dec-12-19 11:56AM  The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech Zacks
Dec-11-19 09:04AM  5 Biotech Stocks Up More Than 100% This Year So Far Zacks
Dec-10-19 07:56AM  The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares Benzinga
Dec-07-19 10:05AM  Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma Business Wire
Dec-06-19 07:39AM  The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend Benzinga +19.08%
Dec-03-19 03:18PM  Epizyme Announces FDA Committee Review of Tazemetostat NDA Zacks
08:54AM  Implied Volatility Surging for Epizyme (EPZM) Stock Options Zacks
Dec-02-19 10:45AM  Epizyme Announces FDA Advisory Committee Meeting to Review Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma Business Wire
Nov-28-19 10:00AM  Epizyme (EPZM) Is Up 6.9% in One Week: What You Should Know Zacks
Nov-26-19 09:38AM  Epizyme, Inc. (EPZM) Shares March Higher, Can It Continue? Zacks
Nov-07-19 06:08AM  These 36 Mass. firms made Deloitte's Technology Fast 500 American City Business Journals +6.59%
Nov-05-19 08:00AM  Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme PR Newswire +18.46%
Nov-04-19 07:00AM  Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement Business Wire +5.15%
Oct-30-19 07:55AM  Epizyme (EPZM) Reports Q3 Loss, Tops Revenue Estimates Zacks +9.57%
06:30AM  Epizyme Announces Positive Pre-NDA Meeting for Tazemetostat for Follicular Lymphoma, Pipeline Updates and Third Quarter 2019 Results Business Wire
Oct-27-19 02:02PM  Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM) Insider Monkey
Oct-15-19 08:37AM  We're Hopeful That Epizyme (NASDAQ:EPZM) Will Use Its Cash Wisely Simply Wall St.
Sep-08-19 09:30AM  Epizyme (EPZM) Up 7% Since Last Earnings Report: Can It Continue? Zacks
Sep-04-19 06:30AM  Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth Business Wire
Aug-29-19 06:30AM  Epizyme to Participate in Upcoming September Conferences Business Wire +5.80%
Aug-16-19 12:32PM  How Should Investors Feel About Epizyme, Inc.'s (NASDAQ:EPZM) CEO Pay? Simply Wall St. +6.94%
Aug-15-19 09:17AM  Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat Zacks
Aug-12-19 08:37AM  Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates Zacks
Aug-09-19 07:55AM  Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates Zacks -5.66%
06:30AM  Epizyme Reports Business Progress and Second Quarter 2019 Results Business Wire
Aug-08-19 10:45AM  Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2 Zacks
10:15AM  Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates Zacks
09:26AM  Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates Zacks
Aug-06-19 06:30AM  Epizyme to Present at the Wedbush PacGrow 2019 Healthcare Conference Business Wire
Jul-31-19 01:48PM  Steven Cohen Charges Into Chiasma
Jul-25-19 10:33AM  Analysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out for Zacks
06:30AM  Epizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma Business Wire
Jul-22-19 06:30AM  Epizyme Strengthens Leadership Team with Appointment of Paolo Tombesi as Chief Financial Officer Business Wire
Jul-12-19 04:53PM  Here's Why Epizyme Rose 103.7% in the First Half of 2019 Motley Fool
Jun-24-19 05:53PM  Epizyme Announces Positive Interim Data on Lead Candidate Zacks
Jun-21-19 07:45AM  Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular Lymphoma Business Wire +10.81%
Jun-15-19 12:38PM  The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs Benzinga
Jun-12-19 06:30AM  Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data Business Wire -13.76%
Jun-11-19 06:57PM  Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM) Insider Monkey
Jun-05-19 09:30AM  Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report? Zacks
Jun-03-19 06:30AM  Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting Business Wire
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Beaulieu JosephCorporate ControllerMar 25Sale15.282123,2394,961Mar 26 09:11 PM
TOMBESI PAOLOChief Financial OfficerMar 25Sale15.281,24318,99315,437Mar 26 09:01 PM
Ros MatthewSee RemarksMar 25Sale15.281,24318,99351,798Mar 26 09:01 PM
Agarwal ShefaliChief Medical OfficerMar 25Sale15.281,24318,99371,991Mar 26 09:00 PM
Bazemore Robert BPresident & CEOMar 25Sale15.283,28550,195254,371Mar 26 09:00 PM
Allen Andrew RDirectorMar 16Option Exercise9.3312,500116,62512,500Mar 18 04:30 PM
Beaulieu JosephCorporate ControllerMar 03Sale22.1899622,0913,617Mar 05 06:52 PM
Agarwal ShefaliChief Medical OfficerJan 27Sale20.442,63053,75758,803Jan 27 09:19 PM
Bazemore Robert BPresident & CEOJan 27Sale20.446,074124,15384,668Jan 27 09:17 PM
Bazemore Robert BPresident & CEOJan 24Sale24.623,00273,90990,742Jan 27 09:17 PM
Ros MatthewSee RemarksJan 24Sale24.641,84745,51042,185Jan 27 09:18 PM
Beaulieu JosephCorporate ControllerJan 24Sale24.633308,1281,042Jan 27 09:16 PM
Agarwal ShefaliChief Medical OfficerJan 24Sale24.641,84345,41261,433Jan 27 09:19 PM
MOTT DAVID MDirectorJun 27Sale12.4352,473652,1340Jun 28 07:05 PM
MOTT DAVID MDirectorJun 26Sale12.8552,472674,17652,473Jun 26 05:16 PM
MOTT DAVID MDirectorJun 25Sale13.3152,472698,649104,945Jun 26 05:16 PM
Agarwal ShefaliChief Medical OfficerJun 14Sale11.971,19514,30435,699Jun 17 05:18 PM
Beaulieu JosephCorporate ControllerJun 13Sale12.102032,456497Jun 14 06:56 PM
Bazemore Robert BPresident & CEOJun 13Sale12.102,07425,09584,994Jun 14 06:53 PM
Ros MatthewSee RemarksJun 13Sale12.101,18514,33939,032Jun 14 06:54 PM